WP
RCKT icon

Woodline Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Woodline Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
+641,222
New +$2.55M 0.01% 792
2025
Q3 		– Sell
-652,865
Closed -$1.6M – 1015
2025
Q2 		$1.6M Hold
652,865
– – 0.01% 755
2025
Q1 		$4.35M Buy
652,865
+444
+0.1% +$4.39K 0.03% 539
2024
Q4 		$8.2M Buy
652,421
+51,358
+9% +$773K 0.06% 390
2024
Q3 		$11.1M Buy
601,063
+39,097
+7% +$801K 0.09% 278
2024
Q2 		$12.1M Buy
+561,966
New +$12.9M 0.12% 228
2023
Q2 		– Sell
-326,605
Closed -$5.59M – 730
2023
Q1 		$5.59M Buy
326,605
+106,352
+48% +$2.08M 0.08% 276
2022
Q4 		$4.31M Buy
+220,253
New +$4.06M 0.06% 341
2022
Q2 		– Sell
-142,011
Closed -$2.25M – 871
2022
Q1 		$2.25M Buy
+142,011
New +$2.45M 0.04% 366

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners's RCKT Position: Q1 2026 in Review

Woodline Partners opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2026: 641,222 shares worth $2.3M. The stake represents 0.01% of the portfolio and ranks #792 among its holdings. This is a return to the name: Woodline Partners previously reported a position in RCKT as recently as Q2 2025.

Woodline Partners first reported a position in RCKT in Q1 2022 and has held it in 9 quarters since. The position peaked at $12.1M in Q2 2024. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Woodline Partners held 641,222 shares of Rocket Pharmaceuticals worth $2.3M as of Q1 2026.
  • Rocket Pharmaceuticals was a new Woodline Partners position in Q1 2026.
  • Rocket Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #792 holding.
  • Woodline Partners first reported a position in Rocket Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
  • Woodline Partners's Rocket Pharmaceuticals position peaked at $12.1M in Q2 2024.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.